Template:Meropenem: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Meropenem}} | |||
{{CMG}} | |||
==Overview== | |||
Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem® and Meronem®. Other brand names include Mepem® (Taiwan) and Meropen® (Japan, Korea). It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.[1] | |||
==FDA Package Insert== | |||
'''[[Meropenem description|Description]]''' | |||
'''| [[Meropenem clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Meropenem microbiology|Microbiology]]''' | |||
'''| [[Meropenem indications and usage|Indications and Usage]]''' | |||
'''| [[Meropenem contraindications|Contraindications]]''' | |||
'''| [[Meropenem warnings|Warnings]]''' | |||
'''| [[Meropenem precautions|Precautions]]''' | |||
'''| [[Meropenem adverse reactions|Adverse Reactions]]''' | |||
'''| [[Meropenem overdosage|Overdosage]]''' | |||
'''| [[Meropenem clinical studies|Clinical Studies]]''' | |||
'''| [[Meropenem dosage and administration|Dosage and Administration]]''' | |||
'''| [[Meropenem compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]''' | |||
'''| [[Meropenem directions for use|Directions For Use]]''' | |||
'''| [[Meropenem how supplied|How Supplied]]''' | |||
'''| [[Meropenem other size packages available|Other Size Packages Available]]''' | |||
'''| [[Meropenem labels and packages|Labels and Packages]]''' | |||
Revision as of 19:16, 19 December 2013
Template loop detected: Template:Meropenem
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem® and Meronem®. Other brand names include Mepem® (Taiwan) and Meropen® (Japan, Korea). It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.[1]
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Other Size Packages Available | Labels and Packages Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
Overview
Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem® and Meronem®. Other brand names include Mepem® (Taiwan) and Meropen® (Japan, Korea). It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.[1]
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Other Size Packages Available | Labels and Packages